| Dr James B Craig, OD | |
|
2032 Veterans Blvd, Dublin, GA 31021-3042 | |
| (478) 272-3445 | |
| (478) 272-4802 |
| Full Name | Dr James B Craig |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | 2032 Veterans Blvd, Dublin, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114967742 | NPI | - | NPPES |
| 003131495A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | OPT000748 (Georgia) | Secondary |
| 152W00000X | Optometrist | OPT000748 (Georgia) | Primary |
| Entity Name | Department Of Behavioral Health And Developmental Disabilities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902030307 PECOS PAC ID: 7416002506 Enrollment ID: O20090825000435 |
News Archive
According to a Kaiser Family Foundation survey, 29 states have streamlined their programs, with most taking advantage of federal incentives to use new technology.
The Kidney Project, a national effort to develop an implantable bio-artificial kidney that could eliminate the need for dialysis, will announce a key milestone in a November 7, 2019 presentation at the American Society of Nephrology Kidney Week 2019 conference in Washington, DC.
Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study in the Journal of General Internal Medicine.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
› Verified 3 days ago
| Entity Name | Myeyedr Optometry Of Georgia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437294592 PECOS PAC ID: 8224261201 Enrollment ID: O20140428000739 |
News Archive
According to a Kaiser Family Foundation survey, 29 states have streamlined their programs, with most taking advantage of federal incentives to use new technology.
The Kidney Project, a national effort to develop an implantable bio-artificial kidney that could eliminate the need for dialysis, will announce a key milestone in a November 7, 2019 presentation at the American Society of Nephrology Kidney Week 2019 conference in Washington, DC.
Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study in the Journal of General Internal Medicine.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
› Verified 3 days ago
| Entity Name | Chance Talley Enterprises Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265097240 PECOS PAC ID: 6002233905 Enrollment ID: O20200824001716 |
News Archive
According to a Kaiser Family Foundation survey, 29 states have streamlined their programs, with most taking advantage of federal incentives to use new technology.
The Kidney Project, a national effort to develop an implantable bio-artificial kidney that could eliminate the need for dialysis, will announce a key milestone in a November 7, 2019 presentation at the American Society of Nephrology Kidney Week 2019 conference in Washington, DC.
Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study in the Journal of General Internal Medicine.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James B Craig, OD 1950 Old Gallows Rd Ste 520, Vienna, VA 22182-3970 Ph: (703) 847-8899 | Dr James B Craig, OD 2032 Veterans Blvd, Dublin, GA 31021-3042 Ph: (478) 272-3445 |
News Archive
According to a Kaiser Family Foundation survey, 29 states have streamlined their programs, with most taking advantage of federal incentives to use new technology.
The Kidney Project, a national effort to develop an implantable bio-artificial kidney that could eliminate the need for dialysis, will announce a key milestone in a November 7, 2019 presentation at the American Society of Nephrology Kidney Week 2019 conference in Washington, DC.
Adult patients with diabetes who trust their medical provider and feel included in treatment decisions are significantly more likely to take and maintain a newly prescribed antidepressant medication, according to a new study in the Journal of General Internal Medicine.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
› Verified 3 days ago